금교창, Keum, Gyo Chang
Principal Researcher
EDUCATION
Ph.D. Seoul National University, Organic Chemistry (2005)
M.S. POSTECH, Organic Chemistry (1992)
B.S. KAIST, Chemistry (1990)
RESEARCH CAREER & ACTIVITIES
- Researcher/Principal Researcher, Korea Institute of Science & Technology (KIST) (1996~)
- Professor, University of Science and Technology (2009~)
- Post-Doc, University of California, Los Angeles (2006-2007)
- Researcher, Hanhyo Institute of Science & technology (1992-1996)
- Steering committee, General Affairs, Korean Chemical Society (2015)
- Administrative staff, Organic Chemistry Division, Korean Chemical Society (2012)
- Vice-president, Organic Chemistry Division, Korean Chemical Society (2017)
- International Advisory Board of ChemMedChem (Wiley) (2018~)
RESEARCH INTERESTS
- Research in Keum’s group is focused on issues in drug discovery and molecular imaging. For the purpose of development of new drug, we utilize salient techniques such as investigating drug targets, designing new scaffolds, establishing synthetic methods, and validating their biological activities. Within the field of molecular imaging, we try to develop new chemical probe for targeting neural signal processing and diagnosis of neurological disorders by modulation of molecular fluorescence spectral and structural properties.
- Through organic and medicinal chemistry, we are working on the following topics.
– Development of new synthetic methods and generation of new scaffolds.
– Drug discovery on various targets in central nervous system (Alzheimer’s disease, neuropathic pain, multiple sclerosis, depression, etc.)
– Drug development of new anticancer, antiviral and antibacterial agents
– Development of molecular imaging probe sensing neurological molecular mechanism
HIGHLIGHT
- Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors. Lee JH, Shin SC, Seo SH, Seo YH, Jeong N, Kim CW, Kim EE,* Keum G.* Bioorg. Med. Chem. Lett. 2017, 27, 237–241.
- Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole derivative with Remarkable Broad Spectrum of Antiproliferative Activity. El-Damasy AK, Cho NC, Nam G, Pae AN, Keum G.* ChemMedChem 2016, 11, 1587–1595.
- Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-RafV600E and C-Raf kinase inhibitory activities. El-Damasy AK, Lee JH, Seo SH, Cho NC, Pae AN, Keum G.* Eur. J. Med. Chem. 2016, 115, 201–216.